Eneas (enalapril maleatee, nitrendipine) tablets №30


Manufacturer: Spain

Treatment of essential hypertension in patients requiring combination therapy.



Eneas Storage
active substances: enalapril maleate; nitrendipine;

1 tablet contains 10 mg of enalapril maleate and 20 mg of nitrendipine;

Eneas excipients: sodium bicarbonate; lactose monohydrate; povidone K 25; microcrystalline cellulose; corn starch; magnesium stearate; sodium lauryl sulfate.

Eneas Dosage form

Main physical and chemical properties: yellow oblong biconvex tablets with embossing “E / N” on one side.

Pharmacotherapeutic group
Drugs that affect the renin-angiotensin system. Angiotensin-converting enzyme inhibitors in combination with calcium antagonists. ATX code C09B B06.

Pharmacological properties


The active compounds contained in the drug Aeneas have a complementary effect.

After absorption, enalapril is hydrolyzed to enalaprilat, which inhibits the angiotensin-converting enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of angiotensin-converting enzyme leads to a decrease in angiotensin II concentrations, an increase in plasma renin activity and a decrease in aldosterone secretion.

The mechanism of action of enalapril is primarily associated with inhibition of the activity of the renin-angiotensin-aldosterone system, which plays an important role in the regulation of blood pressure, so enalapril may also have an antihypertensive effect in patients with low-renin hypertension. Prolonged use of enalapril in patients with primary hypertension and renal failure may improve renal function by increasing glomerular filtration rate.

Treatment of essential hypertension in patients in need of combination therapy.

Aeneas should not be used:

patients with hypersensitivity to enalapril, nitrendipine or to other components of the drug;
patients with a history of angioneurotic edema caused by any angiotensin-converting enzyme (ACE) inhibitor or hereditary / idiopathic angioneurotic edema;
in the II-III trimester of pregnancy (see sections “Features of use” and “Use during pregnancy or breastfeeding”);
patients with unstable hemodynamics, especially after cardiovascular shock, acute heart failure, acute coronary syndrome, acute stroke;
patients with bilateral renal artery stenosis or patients with unilateral renal artery stenosis of a single kidney;
with stenosis of the aorta or mitral valve with severe hemodynamic disorders and hypertrophic cardiomyopathy;
patients with severe renal insufficiency (creatinine clearance less than 10 ml / min) and patients on hemodialysis;
patients with severe hepatic insufficiency;
pregnant women or women planning to become pregnant (see section “Use during pregnancy or breast-feeding”).
Concomitant use of Aeneas with alilskiren in patients with diabetes mellitus or renal impairment (glomerular filtration rate <60 ml / min / 1.73 m2) is contraindicated (see sections “Interaction with other medicinal products and other forms of interaction” and “Pharmacodynamics”).